AMGN Mar 2025 290.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:38AM EDT. Market open.
| Previous close | 38.15 |
| Open | 38.15 |
| Bid | 33.85 |
| Ask | 36.35 |
| Strike | 290.00 |
| Expiry date | 2025-03-21 |
| Day's range | 38.15 - 38.15 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
PR NewswireFDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
ZacksAmgen (AMGN) Stock Sinks As Market Gains: What You Should Know
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.
Investor's Business DailyWhy It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
© 2024 Yahoo. All rights reserved.